Therachon Moves 'Academic Prototype' Towards Clinic
Executive Summary
Emerging Company Profile: Switzerland-based Therachon is developing therapeutics for rare genetic pediatric diseases with a lead program in achondroplasia, also known as genetic dwarfism. CEO Luca Santarelli explains the mechanism behind lead molecule TA-46 and plans moving forward.
You may also be interested in...
Mitsubishi’s Oral Radicava Provides Convenience Option For ALS
Oral or feeding tube administration of the cerebral neuroprotectant should offer flexible dosing options for amyotrophic lateral sclerosis patients, the firm says.
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.
FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump
Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.